The Singapore Clinical Research Institute (SCRI) is a national academic research organization dedicated to enhancing the standards of human clinical research.
As a wholly-owned subsidiary of MOH Holdings, they strive to improve patient care through the design and conduct of cutting-edge clinical research. The highly experienced scientists and operations team at SCRI works closely with their partners, including leading pharmaceutical, medical devices and biotech, as well as academic Investigators.
SCRI collaborates with clinicians to develop specific disease and practice-focused Clinical Research Networks. Through the unique fusion of scientific leadership and operational excellence, SCRI offers a comprehensive suite of clinical research capabilities.
Today, SCRI is also involved in optimising Singapore’s clinical trial landscape through developing numerous National Clinical Trial Coordination Initiatives.
Contact
Address: 31 Biopolis Way, Nanos #02-01 Singapore 138669
Tel.+65 6508 8300
Website: http://www.scri.edu.
CEO and Associate Professor of the Singapore Clinical Research Institute (SCRI) Yee Leong Teoh explains the organization’s pivotal role in supporting and developing Singapore’s clinical research landscape, how these efforts have…
A roundup of some of the most important recent pharma news from the dynamic ASEAN region, including a big new investment from Novartis in its antibody plant in Singapore, the…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
The latest pharma news from Singapore, including J&J Innovation’s continued investment in Singapore; Evotec’s new Singaporean venture, 65LAB; BeiGene’s cancer drug approval in the country; Novo Nordisk’s acquisition of local…
The latest pharma and healthcare news from Southeast Asia, including the partnership between KPJ Healthcare and Samsung; Specialised Therapeutics’ immuno-oncology therapy; Singapore biotech CytoMed Therapeutics’ IPO, the Malaysian approval of…
The latest pharma and healthcare news from Southeast Asia, including the proposed healthcare programs of Thailand’s political parties for the upcoming election; Singapore’s approval of Pfizer’s 20-valent pneumococcal conjugate vaccine;…
The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share…
MSD is set to inject an additional USD 500 million into its existing Singapore manufacturing operations with two new facilities to produce vaccines and biologics. One of the new plants…
On World Heart Day 2022 Iris Zemzoum of Novartis Asia Pacific, Middle East & Africa (APMA) outlines the devastating impact of cardiovascular disease (CVD) as well as Novartis’ multipronged approach…
Japanese giant Takeda has a new Head for APAC; Indian national Dr Mahender Nayak, previously the firm’s India, CIS, Middle East, Turkey & Africa (ICMEA) lead. Nayak will relocate to…
The latest healthcare and pharma news from Singapore, including the partnership between Boehringer Ingelheim and A*STAR for targeted cancer therapies, Amgen’s sponsorship of biotech incubator, NSG BioLabs, and Tessa Therapeutics’…
The latest pharma news from Southeast Asia, including the Singaporean Health Sciences Authority (HSA) being awarded the highest maturity level in the WHO’s classification of global regulatory authorities, as well…
Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for…
See our Cookie Privacy Policy Here
